Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Conference News AHA 2018

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Yael L. Maxwell

November 16, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

AHA Puts Focus on the Impact of Violence on Cardiovascular Health

Todd Neale

November 14, 2018

News Conference News AHA 2018

Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI

Michael O'Riordan

November 14, 2018

News Conference News AHA 2018

TiCAB: Ticagrelor No Help for Preventing Graft Failure Post-CABG

Shelley Wood

November 13, 2018

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Caitlin E. Cox

November 13, 2018

News Conference News AHA 2018

Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages

Michael O'Riordan

November 12, 2018

Presentation AHA 2018

PIONEER Trial: Angiotensin Receptor-NeprilysinInhibition in Patients Hospitalized With Acute Decompensated Heart Failure

Presenter: Eric J Velazquez

November 12, 2018

News Conference News AHA 2018

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

Michael O'Riordan

November 11, 2018

Presentation AHA 2018

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Presenter: Sotirios Tsimikas

November 11, 2018

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Shelley Wood

November 11, 2018

News Conference News AHA 2018

Post-MI Yoga: Randomized Trial Shows Feasibility and Safety as an Option for Cardiac Rehab

Yael L. Maxwell

November 10, 2018

News Conference News AHA 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

Todd Neale

November 10, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

Shelley Wood

November 10, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Conference News AHA 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Michael O'Riordan

November 10, 2018

Advertisement

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

AHA Puts Focus on the Impact of Violence on Cardiovascular Health

Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI

TiCAB: Ticagrelor No Help for Preventing Graft Failure Post-CABG

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages

PIONEER Trial: Angiotensin Receptor-NeprilysinInhibition in Patients Hospitalized With Acute Decompensated Heart Failure

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Post-MI Yoga: Randomized Trial Shows Feasibility and Safety as an Option for Cardiac Rehab

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content